cixutumumab (100)(62)

Structure	 

Heavy chain / Chaone lourde / Cadena pesada

EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG  50

IIPIFGTANY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARAP 100

LRFLEWSTQD HYYYYYMDVW GKGTTVTVSS ASTKGPSVFP LAPSSKSTSG 150

GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT 200

VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 250

PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA 300

KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS 350

KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 400

ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT 450

QKSLSLSPGK                                             460

Light chain / Chaone lygire / Cadena ligera

SSELTQDPAV SVALGQTVRI TCQGDSLRSY YATWYQQKPG QAPILVIYGE  50

NKRPSGIPDR FSGSSSGNTA SLTITGAQAE DEADYYCKSR DGSGQHLVFG 100

GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150

KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200

GSTVEKTVAP AECS                                        214

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

Intra-H	22-96	157-213	274-334	380-438

	22??-96??	157??-213??	274??-334??	380??-438??

Intra-L	22?-87?	136?-195?



	22???-87???	136???-195???



Inter-H-L	233-213?	233??-213???



Inter-H-H	239-239??	242-242??





N-glycosylation sites / Sites de N-glycosylation / Posiciones de
N-glicosilaciun

310, 310??

Molecular formula	C6500H10052N1724O2036S44

Description

immunoglobulin G1-lambda, anti-[Homo sapiens insulin-like growth factor
I receptor (IGF-1R, CD221)], Homo sapiens monoclonal antibody;

gamma1 heavy chain (1-460) [Homo sapiens VH (IGHV1-69*06 (99.00%)
-(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K (131-460)],
(233-213?)-disulfide with lambda light chain (1?-214?) [Homo sapiens
V-LAMBDA (IGLV3-19*01 (92.70%) -IGLJ2*01) [6.3.11] (1?-108?) -IGLC2*01,
T124>A (109?-214?)]; (239-239??:242-242??)-bisdisulfide dimer 

	

WHO 

International Nonproprietary Names Programme	

9099

December 2008

Page 1/1

		

